First Citizens Bank & Trust Co. Sells 3,169 Shares of Johnson & Johnson (NYSE:JNJ)

First Citizens Bank & Trust Co. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,744 shares of the company’s stock after selling 3,169 shares during the period. First Citizens Bank & Trust Co.’s holdings in Johnson & Johnson were worth $10,231,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Dark Forest Capital Management LP bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $223,000. Invst LLC boosted its stake in Johnson & Johnson by 11.7% in the second quarter. Invst LLC now owns 2,083 shares of the company’s stock worth $305,000 after buying an additional 218 shares in the last quarter. Quarry LP purchased a new position in shares of Johnson & Johnson during the second quarter worth approximately $49,000. Gateway Wealth Partners LLC lifted its holdings in shares of Johnson & Johnson by 12.6% in the 2nd quarter. Gateway Wealth Partners LLC now owns 2,412 shares of the company’s stock worth $352,000 after acquiring an additional 270 shares during the last quarter. Finally, Truist Financial Corp raised its position in Johnson & Johnson by 4.9% in the 2nd quarter. Truist Financial Corp now owns 2,122,856 shares of the company’s stock worth $310,277,000 after purchasing an additional 98,903 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Down 1.5 %

Shares of Johnson & Johnson stock opened at $150.63 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The firm has a market cap of $362.65 billion, a price-to-earnings ratio of 22.65, a PEG ratio of 2.45 and a beta of 0.51. The company has a 50-day moving average of $147.81 and a 200 day moving average of $156.12. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period last year, the business earned $2.29 earnings per share. The business’s revenue was up 5.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Bank of America lowered their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective on the stock. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $170.44.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.